We speculate that c-myc, an oncogene that is frequently misregulated in prostate cancer [26, 27] and is a known transcriptional regulator of IRP2 [28], may be the driver of IRP2 overexpression in some prostate tumors. Here, MYC is linked to prostate neoplasm.